Manufacturer

Hospira, Inc.

Country

USA

Certificates

FDA

Document

1.67 MB

Registration Date	3 Oct 2016
Share

Docetaxel®

(0)

Medicine Pharmaceuticals Product Number : 0409-0201-25

Antineoplastic Agent

Drug Information

Generic

Docetaxel

NDC Code

0409-0201-25

Drug Class

Mitotic inhibitors

Therapeutic Class

Antineoplastic Agent

Dosage form

Solution

Route of Administration

Intravenous Injection

Therapeutic Area

1.Adenocarcinoma of the oesophagus, metastatic breast cancer and acute lymphoblastic leukemia

Indication

Docetaxel is used in the treatment of a variety of cancers including: breast, lung, prostate, gastric, head and neck, and ovarian cancer.[9] Clinical data has shown docetaxel to have cytotoxic activity against breast, colorectal, lung, ovarian, prostate, liver, renal, gastric, head and neck cancers, and melanoma.[10] In hormone refractory prostate cancer docetaxel improves life expectancy and overall life quality.

Benefit

For the first time, an improvement in overall survival has been observed with tolerable adjuvant chemotherapy for localized prostate cancer.